08/30/2017

NCCN has published updates to the NCCN Guidelines® and the NCCN Compendium® for Acute Lymphoblastic Leukemia

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) and the NCCN Drugs and Biologics Compendium (NCCN Compendium^®) for Acute Lymphoblastic Leukemia. These NCCN Guidelines^® are currently available as Version 2.2017. 

• Relapsed/Refractory Disease (ALL-9)
  • Ph-positive ALL
    • Inotuzumab ozogamicin (category 2A) added as a treatment option for patients intolerant to TKIs or with disease refractory to TKIs.
  • Ph-negative ALL
    • Inotuzumab ozogamicin (category 1) added as a treatment option.
  • Regimens for Relapsed/Refractory ALL (ALL-D 3 of 5)
    • Footnote "j" added: Inotuzumab ozogamicin is associated with hepatotoxicity, including fatal and life-threatening hepatic veno-occlusive disease, and increased risk of post-hematopoietic stem cell transplant (HSCT) non-relapse mortality. For details, see: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761040s000lbl.pdf.
    • Ph-positive ALL
      • Inotuzumab ozogamicin (category 2A) added as a treatment option for patients intolerant to TKIs or with disease refractory to TKIs.
    • Ph-negative ALL
      • Inotuzumab ozogamicin (category 1) added as a treatment option.